Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
- 23 October 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (515)
Abstract
Rotavirus vaccines have oncolytic properties and can overcome resistance to anti–PD-(L)1/CTLA-4 via RIG-I activation upon intratumoral administration.Keywords
Funding Information
- Ligue Contre le Cancer
- Institut National Du Cancer (PRTK14_061)
- Institut National Du Cancer (LYRICAN, INCa-DGOS-Inserm_12563)
- Les 111 des Arts
- Torocinelles
- LabEx DEvweCAN (ANR-10-LABX-0061)
- ALBEC
- Institut d’Hématologie et d’Oncologie Pédiatrique
This publication has 37 references indexed in Scilit:
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockadeBritish Journal of Cancer, 2018
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsCancer Discovery, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyNature Reviews Cancer, 2016
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with IpilimumabClinical Cancer Research, 2015
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patientsProceedings of the National Academy of Sciences, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014